Cart
sales@molnova.com
Corr4A
CAS No. 421580-53-2
Corr4A( Corr 4A )
Catalog No. M14435 CAS No. 421580-53-2
A small molecule corrector of ΔF508-CFTR with IC50 of 6.0 uM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 435 | Get Quote |
|
| 50MG | 1341 | Get Quote |
|
| 100MG | 1773 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCorr4A
-
NoteResearch use only, not for human use.
-
Brief DescriptionA small molecule corrector of ΔF508-CFTR with IC50 of 6.0 uM.
-
DescriptionA small molecule corrector of ΔF508-CFTR with IC50 of 6.0 uM.
-
In Vitro——
-
In Vivo——
-
SynonymsCorr 4A
-
PathwayApoptosis
-
TargetCFTR
-
RecptorCFTR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number421580-53-2
-
Formula Weight456.963
-
Molecular FormulaC21H17ClN4O2S2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC1=C(C2=CSC(NC3=CC(Cl)=CC=C3OC)=N2)SC(NC(C4=CC=CC=C4)=O)=N1
-
Chemical NameN-[2-(5-chloro-2-methoxy-phenylamino)-4'-methyl-[4,5']bithiazolyl-2'-yl]-benzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Boinot C, et al. J Pharmacol Exp Ther. 2014 Sep;350(3):624-34.
2. Talebian L, et al. Cell Physiol Biochem. 2009;23(1-3):199-204.
3. Coffman KC, et al. J Med Chem. 2014 Aug 14;57(15):6729-38.
4. Pedemonte N, et al. Mol Pharmacol. 2005 Dec;68(6):1736-46.
molnova catalog
related products
-
UCCF-853
UCCF-853 is a small-molecule CFTR modulator that can be used to study cystic fibrosis.
-
IOWH-032
A novel and potent CFTR inhibitor (IC50=1.01 uM) in T84 and CHO-CFTR cell based assays for the treatment of cystic fibrosis; potentially serves as lead compound for development of new drugs for the treatment of cystic fibrosis.
-
Astressin 2B
Potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist (IC50 values are 1.3 and > 500 nM for CRF2 and CRF1 respectively). Antagonizes CRF2-mediated inhibition of gastric emptying.
